Oncolytic virus extends survival in medulloblastoma model

February 15, 2012, Ohio State University Medical Center

A strain of measles virus engineered to kill cancer cells prolongs survival in a model of medulloblastoma that is disseminated in the fluid around the brain, according to a new study by researchers at Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and the Mayo Clinic. Treatment with the oncolytic virus called MV-GFP extended survival of animals with disseminated human medulloblastoma up to 122 percent, with treated animals surviving 82 days on average versus 37 days for controls. Two of the eight treated animals were left cancer-free.

The findings, published online in the journal Neuro-Oncology, could lead to a safer, more effective therapy for , and particularly for disseminated medulloblastoma, the researchers say.

Medulloblastoma accounts for 15 to 20 percent of all childhood brain tumors, with 350 to 400 new cases diagnosed annually in the United States.

Untreated, medulloblastoma is fatal. Current therapy for the disease involves surgery, multidrug chemotherapy and radiation therapy to the entire brain. Five-year survival is about 60 percent, but the extensive radiation therapy often leads to decreased intelligence.

Furthermore, in about 20 percent of newly diagnosed patients and 75 percent of patients with recurrent disease, the tumor has disseminated into the cerebrospinal fluid. Five-year survival for these children is less than 20 percent.

"Patients whose tumor has spread into the fluid around the brain and spinal cord have an especially grim prognosis," says principal investigator Dr. Cory Raffel, professor and vice-chair of neurological surgery.

"Because dissemination of tumor carries a grave prognosis, any treatment that can effectively treat this condition while avoiding could potentially improve survival in these patients and quality of life for survivors."

For this study, Raffel and his collaborators used two human medulloblastoma cell lines that they labeled with firefly luciferase, making the cells bioluminescent and enabling the researchers to track them as they dispersed in the living animal and responded to treatment with the oncolytic virus.

Three or 14 days after the were implanted in the ; the oncolytic virus was injected at the same location in five doses.

In the first medulloblastoma cell line tested, treated animals lived an average of 82 days compared with 37 days for the controls. Two of the eight animals were cured of the disseminated disease, which was determined first according to bioluminescent imaging, then histologically.

In a second experiment using a more virulent human medulloblastoma cell line, treated animals survived 37 days versus 16 days for controls, with one animal left cancer free.

Currently, the investigators are conducting studies to determine optimal dosing of the in preparation for a phase I clinical trial in humans.

Explore further: New oncolytic virus shows improved effectiveness in preclinical testing

Related Stories

New oncolytic virus shows improved effectiveness in preclinical testing

October 27, 2011
A new fourth-generation oncolytic virus designed to both kill cancer cells and inhibit blood-vessel growth has shown greater effectiveness than earlier versions when tested in animal models of human brain cancer.

Could targeting a virus treat a common pediatric brain tumor?

September 26, 2011
Medulloblastomas are the most common cancerous (malignant) brain tumors in children. Although survival rates have improved over the years, medulloblastoma remains associated with substantial mortality, and long-term survivors ...

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.